Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samar Alanazi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Oman Journal of Ophthalmology|December 9, 2024
Early visual and clinical outcomes of transepithelial photorefractive keratectomy versus transepithelial keratectomy with smart pulse technology for myopiaTurad Alkadi, Samar Alanazi, Abdulrahman Algwaiz, et al.
Oncology Reviews|July 31, 2018
HER3 signaling and targeted therapy in cancerRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Dentistry Journal|February 26, 2026
Assessment of Language Barriers Between Dental Students and Patients in Riyadh, Saudi Arabia-A Mixed Methods StudySanjeev B Khanagar, Samar Alanazi, Razan Alotaibi, et al.
International Journal of Molecular Sciences|April 3, 2021
PI3K Inhibitors in Cancer: Clinical Implications and Adverse EffectsRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Cancers|November 27, 2021
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant MelanomaHima Patel, Rosalin Mishra, Nour Yacoub, et al.
Cancers|June 27, 2020
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species LevelsLong Yuan, Rosalin Mishra, Hima Patel, et al.
Cancers|February 26, 2020
Current Advances in the Treatment of BRAF-Mutant MelanomaHima Patel, Nour Yacoub, Rosalin Mishra, et al.
Oncotarget|July 3, 2018
Activating HER3 mutations in breast cancerRosalin Mishra, Samar Alanazi, Long Yuan, et al.
Cancers|December 23, 2022
HER3 Alterations in Cancer and Potential Clinical ImplicationsMary Kate Kilroy, SoYoung Park, Wasim Feroz, et al.
International Journal of Molecular Sciences|March 6, 2021
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell GrowthRosalin Mishra, Long Yuan, Hima Patel, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Oman Journal of Ophthalmology|December 9, 2024
Early visual and clinical outcomes of transepithelial photorefractive keratectomy versus transepithelial keratectomy with smart pulse technology for myopiaTurad Alkadi, Samar Alanazi, Abdulrahman Algwaiz, et al.
Oncology Reviews|July 31, 2018
HER3 signaling and targeted therapy in cancerRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Dentistry Journal|February 26, 2026
Assessment of Language Barriers Between Dental Students and Patients in Riyadh, Saudi Arabia-A Mixed Methods StudySanjeev B Khanagar, Samar Alanazi, Razan Alotaibi, et al.
International Journal of Molecular Sciences|April 3, 2021
PI3K Inhibitors in Cancer: Clinical Implications and Adverse EffectsRosalin Mishra, Hima Patel, Samar Alanazi, et al.
Cancers|November 27, 2021
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant MelanomaHima Patel, Rosalin Mishra, Nour Yacoub, et al.
Cancers|June 27, 2020
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species LevelsLong Yuan, Rosalin Mishra, Hima Patel, et al.
Cancers|February 26, 2020
Current Advances in the Treatment of BRAF-Mutant MelanomaHima Patel, Nour Yacoub, Rosalin Mishra, et al.
Oncotarget|July 3, 2018
Activating HER3 mutations in breast cancerRosalin Mishra, Samar Alanazi, Long Yuan, et al.
Cancers|December 23, 2022
HER3 Alterations in Cancer and Potential Clinical ImplicationsMary Kate Kilroy, SoYoung Park, Wasim Feroz, et al.
International Journal of Molecular Sciences|March 6, 2021
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell GrowthRosalin Mishra, Long Yuan, Hima Patel, et al.
Pageof 1